top of page


For inquiries about any news items, email:

Sept. 29, 2022

ML161 (aka Parmodulin 2) greatly improves kidney function in a mouse model of diabetic kidney disease

Sept. 13, 2022

Paul Ornstein, Ph.D. joins as VP of Preclinical Development

Apr. 15, 2022

Function Therapeutics receives Dept. of Defense award.

Sept. 28, 2021

U.S. patent #11,130,743 has been granted.

Nov. 11, 2021

Function Therapeutics, Inc. has incorporated.

Oct. 15, 2020

Function Therapeutics announces initial Scientific Advisory Board members.

bottom of page